Tower Research Capital LLC TRC Makes New $30,000 Investment in KALA BIO, Inc. (NASDAQ:KALA)

Tower Research Capital LLC TRC purchased a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,357 shares of the company’s stock, valued at approximately $30,000.

Separately, Knights of Columbus Asset Advisors LLC lifted its stake in KALA BIO by 100.0% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 4,834 shares of the company’s stock valued at $34,000 after acquiring an additional 2,417 shares during the period. Hedge funds and other institutional investors own 24.61% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on KALA. HC Wainwright reduced their price target on shares of KALA BIO from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 target price on shares of KALA BIO in a research report on Monday, April 1st.

KALA BIO Stock Performance

KALA BIO stock traded up $0.25 during mid-day trading on Friday, reaching $7.01. 4,531 shares of the stock traded hands, compared to its average volume of 11,435. KALA BIO, Inc. has a 12-month low of $5.10 and a 12-month high of $19.35. The business’s 50-day moving average is $7.34 and its 200-day moving average is $7.11. The company has a debt-to-equity ratio of 5.10, a current ratio of 6.33 and a quick ratio of 6.33. The stock has a market capitalization of $19.73 million, a PE ratio of -0.39 and a beta of -1.75.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings results on Friday, March 29th. The company reported ($3.18) EPS for the quarter. As a group, sell-side analysts predict that KALA BIO, Inc. will post -11.28 EPS for the current fiscal year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery.